Clinical Advances in Hematology & Oncology最新文献_第4页

Choosing between CAR T-cell therapy and pirtobrutinib in double-refractory CLL. 在CAR - t细胞治疗和匹托鲁替尼治疗双难治性CLL之间的选择。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2024-12-01

Kerry A Rogers

引用次数: 0

The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas. 双特异性t细胞接合体在滤泡性和大b细胞淋巴瘤治疗中的出现。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2024-12-01

Forat G Lutfi, Nausheen Ahmed, Marc S Hoffmann, Aung Tun, Joseph P McGuirk

引用次数: 0

Targeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma. 靶向免疫疗法治疗儿童和青少年经典霍奇金淋巴瘤。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2024-12-01

Ana C Xavier, Jessica Hochberg, Mitchell S Cairo

{"title":"Targeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma.","authors":"Ana C Xavier, Jessica Hochberg, Mitchell S Cairo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Childhood and adolescent classic Hodgkin Lymphoma (cHL) has long been a model for how we balance improved outcomes with increased toxicities in pediatric cancer. The recognition that unacceptable short- and long-term toxicities come with increasing intensity of treatment has led to a decades-long attempt to better understand the patient-specific factors that dictate responses and outcomes. Targeted immunotherapy has emerged as a promising adjunct to cancer treatment; it has been shown to improve outcomes for poorly responding patients, to salvage relapsed disease, and more recently, to replace more toxic therapy modalities such as chemotherapy and radiation while maintaining excellent outcomes. Targeted antibody therapy for cHL--whether it be naked, conjugated, or bispecific--has been proven effective and well tolerated in the pediatric population. Targets include both Reed-Sternberg cells and the tumor microenvironment, and therapy can be directed against cell surface proteins or immune checkpoint blockade. Ongoing adult and pediatric cell therapy trials in which CD30-targeting chimeric antigen receptor T-cell therapy is used for patients with relapsed or refractory disease will determine the best approaches for these high-risk patients. As a result of innovations in tumor biology, the development of novel immunotherapy agents, and a better understanding of toxicities, targeted immunotherapy is now a component not only of the treatment of pediatric cHL but also of cancer treatment paradigms overall.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"22 10","pages":"520-530"},"PeriodicalIF":1.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporating PSMA PET imaging into the treatment plan for newly diagnosed and recurrent prostate cancer. 将PSMA PET成像纳入新诊断和复发前列腺癌的治疗方案。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2024-12-01

Neal Shore

引用次数: 0

The use of zenocutuzumab for NRG1 fusion-positive tumors. zenocutuzumab用于NRG1融合阳性肿瘤。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2024-12-01

Alison Schram

引用次数: 0

Highlights in neuroendocrine tumors from the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium: commentary. 来自2024年北美神经内分泌肿瘤学会（NANETS）多学科网络医学研讨会的神经内分泌肿瘤亮点：评论。